Teplizumab is clinically approved for delaying the onset of type 1 diabetes, with the responses affected by EBV serology status. Here the authors pursue immune profiling of EBV+ or EBV- participants before and after teplizumab treatment to find more pronounced immune modulation in treated EBV+ individuals to hint a cellular mechanism for this EBV effect.
- Ana Lledó-Delgado
- Paula Preston-Hurlburt
- Kevan C. Herold
